Audree B Tadros1, Hannah Y Wen2, Monica Morrow3. 1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. morrowm@mskcc.org.
Abstract
BACKGROUND/ OBJECTIVE: Cancers classified as "special histologic subtypes" are felt to have a good prognosis. We used the 21-gene Oncotype DX Breast Recurrence Score® multigene assay to examine prognostic variation within special histologic subtypes. We also examined the Recurrence Score® (RS) distribution among the more common ductal (IDC) and lobular (ILC) cancers. METHODS: 610,350 tumor specimens examined in the Genomic Health clinical laboratory from 2/2004 to 8/2017 were included. Specimen histology was classified centrally using a single H&E slide and World Health Organization criteria. RS distribution (low < 18, intermediate 18-30, and high ≥ 31) was compared among histologic subtypes. RESULTS: Median patient age was 60 years (IQR 51-67); 80% were node negative. Most patients had low RS results (59.2%); only 9.5% had high results. The lowest mean RS was seen in the papillary subtype (11); the highest in the IDC group (18.4). Mean RS for all special subtypes was lower than that of IDC patients. When the high RS threshold was decreased from 31 to 25, as used in the TAILORx and RxPONDER trials, the number of high RS-result patients increased from 9.5% to 16.8%. Patients with ILC had a lower mean RS result than patients with IDC, 16.5 versus 18.4. CONCLUSION: There is substantial diversity in predicted prognosis among patients with cancers classified as special histologic subtypes, with 12-25% having intermediate RS results and 0.5-9% having high RS results. Pending further definition of the role of chemotherapy for patients with intermediate RS results by TAILORx and RxPONDER, the RS result may help to inform systemic therapy decisions in these patients.
BACKGROUND/ OBJECTIVE:Cancers classified as "special histologic subtypes" are felt to have a good prognosis. We used the 21-gene Oncotype DX Breast Recurrence Score® multigene assay to examine prognostic variation within special histologic subtypes. We also examined the Recurrence Score® (RS) distribution among the more common ductal (IDC) and lobular (ILC) cancers. METHODS: 610,350 tumor specimens examined in the Genomic Health clinical laboratory from 2/2004 to 8/2017 were included. Specimen histology was classified centrally using a single H&E slide and World Health Organization criteria. RS distribution (low < 18, intermediate 18-30, and high ≥ 31) was compared among histologic subtypes. RESULTS: Median patient age was 60 years (IQR 51-67); 80% were node negative. Most patients had low RS results (59.2%); only 9.5% had high results. The lowest mean RS was seen in the papillary subtype (11); the highest in the IDC group (18.4). Mean RS for all special subtypes was lower than that of IDC patients. When the high RS threshold was decreased from 31 to 25, as used in the TAILORx and RxPONDER trials, the number of high RS-result patients increased from 9.5% to 16.8%. Patients with ILC had a lower mean RS result than patients with IDC, 16.5 versus 18.4. CONCLUSION: There is substantial diversity in predicted prognosis among patients with cancers classified as special histologic subtypes, with 12-25% having intermediate RS results and 0.5-9% having high RS results. Pending further definition of the role of chemotherapy for patients with intermediate RS results by TAILORx and RxPONDER, the RS result may help to inform systemic therapy decisions in these patients.
Authors: Gulisa Turashvili; Edi Brogi; Monica Morrow; Clifford Hudis; Maura Dickler; Larry Norton; Hannah Y Wen Journal: Breast Cancer Res Treat Date: 2017-06-03 Impact factor: 4.872
Authors: Catherine M Kelly; Savitri Krishnamurthy; Giampaolo Bianchini; Jennifer K Litton; Ana M Gonzalez-Angulo; Gabriel N Hortobagyi; Lajos Pusztai Journal: Cancer Date: 2010-11-15 Impact factor: 6.860
Authors: Bernhard C Pestalozzi; David Zahrieh; Elizabeth Mallon; Barry A Gusterson; Karen N Price; Richard D Gelber; Stig B Holmberg; Jurij Lindtner; Raymond Snyder; Beat Thürlimann; Elizabeth Murray; Giuseppe Viale; Monica Castiglione-Gertsch; Alan S Coates; Aron Goldhirsch Journal: J Clin Oncol Date: 2008-05-05 Impact factor: 44.544
Authors: Otto Metzger Filho; Anita Giobbie-Hurder; Elizabeth Mallon; Barry Gusterson; Giuseppe Viale; Eric P Winer; Beat Thürlimann; Richard D Gelber; Marco Colleoni; Bent Ejlertsen; Marc Debled; Karen N Price; Meredith M Regan; Alan S Coates; Aron Goldhirsch Journal: J Clin Oncol Date: 2015-07-27 Impact factor: 44.544
Authors: Scott D Ramsey; William E Barlow; Ana M Gonzalez-Angulo; Sean Tunis; Laurence Baker; John Crowley; Patricia Deverka; David Veenstra; Gabriel N Hortobagyi Journal: Contemp Clin Trials Date: 2012-09-18 Impact factor: 2.226
Authors: Michael J Hassett; Samuel M Silver; Melissa E Hughes; Douglas W Blayney; Stephen B Edge; James G Herman; Clifford A Hudis; P Kelly Marcom; Jane E Pettinga; David Share; Richard Theriault; Yu-Ning Wong; Jonathan L Vandergrift; Joyce C Niland; Jane C Weeks Journal: J Clin Oncol Date: 2012-05-14 Impact factor: 44.544
Authors: Jason A Mouabbi; Amy Hassan; Bora Lim; Gabriel N Hortobagyi; Debasish Tripathy; Rachel M Layman Journal: Breast Cancer Res Treat Date: 2022-03-26 Impact factor: 4.872
Authors: Matthias Christgen; Leonie Donata Kandt; Wiebke Antonopoulos; Stephan Bartels; Mieke R Van Bockstal; Martin Bredt; Maria Jose Brito; Henriette Christgen; Cecile Colpaert; Bálint Cserni; Gábor Cserni; Maximilian E Daemmrich; Raihanatou Danebrock; Franceska Dedeurwaerdere; Carolien Hm van Deurzen; Ramona Erber; Christine Fathke; Henning Feist; Maryse Fiche; Claudia Aura Gonzalez; Natalie D Ter Hoeve; Loes Kooreman; Till Krech; Glen Kristiansen; Janina Kulka; Florian Laenger; Marcel Lafos; Ulrich Lehmann; Maria Dolores Martin-Martinez; Sophie Mueller; Enrico Pelz; Mieke Raap; Alberto Ravarino; Tanja Reineke-Plaass; Nora Schaumann; Anne-Marie Schelfhout; Maxim De Schepper; Jerome Schlue; Koen Van de Vijver; Wim Waelput; Axel Wellmann; Monika Graeser; Oleg Gluz; Sherko Kuemmel; Ulrike Nitz; Nadia Harbeck; Christine Desmedt; Giuseppe Floris; Patrick Wb Derksen; Paul J van Diest; Anne Vincent-Salomon; Hans Kreipe Journal: J Pathol Clin Res Date: 2021-12-10
Authors: Gábor Rubovszky; Judit Kocsis; Katalin Boér; Nataliya Chilingirova; Magdolna Dank; Zsuzsanna Kahán; Dilyara Kaidarova; Erika Kövér; Bibiana Vertáková Krakovská; Károly Máhr; Bela Mriňáková; Béla Pikó; Ivana Božović-Spasojević; Zsolt Horváth Journal: Pathol Oncol Res Date: 2022-07-11 Impact factor: 2.874